REPORT ID 4308

Global Oral hypoglycemic agents and insulin analogues Market Research Report 2017

Publish Date
18-Dec-17
Pages
100
Format
Electronic (PDF)

In this report, the global Oral hypoglycemic agents and insulin analogues market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Oral hypoglycemic agents and insulin analogues in these regions, from 2012 to 2022 (forecast), covering
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
Global Oral hypoglycemic agents and insulin analogues market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
    Sanofi-Aventis
    Ganlee
    Biocon
    Novo Nordisk
    Eli Lilly
    Tonghua Dongbao
    United Laboratory
    Jiangsu Wanbang
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Insulin Secretagogues
    Alpha-glucosidase Inhibitors
    Insulin Sensitizers
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
    Hospitals
    Drug Store
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Global Oral hypoglycemic agents and insulin analogues Market Research Report 2017
1 Oral hypoglycemic agents and insulin analogues Market Overview
    1.1 Product Overview and Scope of Oral hypoglycemic agents and insulin analogues
    1.2 Oral hypoglycemic agents and insulin analogues Segment by Type (Product Category)
        1.2.1 Global Oral hypoglycemic agents and insulin analogues Production and CAGR (%) Comparison by Type (Product Category)(2012-2022)
        1.2.2 Global Oral hypoglycemic agents and insulin analogues Production Market Share by Type (Product Category) in 2016
        1.2.3 Insulin Secretagogues
        1.2.4 Alpha-glucosidase Inhibitors
        1.2.5 Insulin Sensitizers
    1.3 Global Oral hypoglycemic agents and insulin analogues Segment by Application
        1.3.1 Oral hypoglycemic agents and insulin analogues Consumption (Sales) Comparison by Application (2012-2022)
        1.3.2 Hospitals
        1.3.3 Drug Store
        1.3.4 Others
    1.4 Global Oral hypoglycemic agents and insulin analogues Market by Region (2012-2022)
        1.4.1 Global Oral hypoglycemic agents and insulin analogues Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
        1.4.2 North America Status and Prospect (2012-2022)
        1.4.3 Europe Status and Prospect (2012-2022)
        1.4.4 China Status and Prospect (2012-2022)
        1.4.5 Japan Status and Prospect (2012-2022)
        1.4.6 Southeast Asia Status and Prospect (2012-2022)
        1.4.7 India Status and Prospect (2012-2022)
    1.5 Global Market Size (Value) of Oral hypoglycemic agents and insulin analogues (2012-2022)
        1.5.1 Global Oral hypoglycemic agents and insulin analogues Revenue Status and Outlook (2012-2022)
        1.5.2 Global Oral hypoglycemic agents and insulin analogues Capacity, Production Status and Outlook (2012-2022)

2 Global Oral hypoglycemic agents and insulin analogues Market Competition by Manufacturers
    2.1 Global Oral hypoglycemic agents and insulin analogues Capacity, Production and Share by Manufacturers (2012-2017)
        2.1.1 Global Oral hypoglycemic agents and insulin analogues Capacity and Share by Manufacturers (2012-2017)
        2.1.2 Global Oral hypoglycemic agents and insulin analogues Production and Share by Manufacturers (2012-2017)
    2.2 Global Oral hypoglycemic agents and insulin analogues Revenue and Share by Manufacturers (2012-2017)
    2.3 Global Oral hypoglycemic agents and insulin analogues Average Price by Manufacturers (2012-2017)
    2.4 Manufacturers Oral hypoglycemic agents and insulin analogues Manufacturing Base Distribution, Sales Area and Product Type
    2.5 Oral hypoglycemic agents and insulin analogues Market Competitive Situation and Trends
        2.5.1 Oral hypoglycemic agents and insulin analogues Market Concentration Rate
        2.5.2 Oral hypoglycemic agents and insulin analogues Market Share of Top 3 and Top 5 Manufacturers
        2.5.3 Mergers & Acquisitions, Expansion

3 Global Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue (Value) by Region (2012-2017)
    3.1 Global Oral hypoglycemic agents and insulin analogues Capacity and Market Share by Region (2012-2017)
    3.2 Global Oral hypoglycemic agents and insulin analogues Production and Market Share by Region (2012-2017)
    3.3 Global Oral hypoglycemic agents and insulin analogues Revenue (Value) and Market Share by Region (2012-2017)
    3.4 Global Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.5 North America Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.6 Europe Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.7 China Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.8 Japan Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.9 Southeast Asia Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.10 India Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

4 Global Oral hypoglycemic agents and insulin analogues Supply (Production), Consumption, Export, Import by Region (2012-2017)
    4.1 Global Oral hypoglycemic agents and insulin analogues Consumption by Region (2012-2017)
    4.2 North America Oral hypoglycemic agents and insulin analogues Production, Consumption, Export, Import (2012-2017)
    4.3 Europe Oral hypoglycemic agents and insulin analogues Production, Consumption, Export, Import (2012-2017)
    4.4 China Oral hypoglycemic agents and insulin analogues Production, Consumption, Export, Import (2012-2017)
    4.5 Japan Oral hypoglycemic agents and insulin analogues Production, Consumption, Export, Import (2012-2017)
    4.6 Southeast Asia Oral hypoglycemic agents and insulin analogues Production, Consumption, Export, Import (2012-2017)
    4.7 India Oral hypoglycemic agents and insulin analogues Production, Consumption, Export, Import (2012-2017)

5 Global Oral hypoglycemic agents and insulin analogues Production, Revenue (Value), Price Trend by Type
    5.1 Global Oral hypoglycemic agents and insulin analogues Production and Market Share by Type (2012-2017)
    5.2 Global Oral hypoglycemic agents and insulin analogues Revenue and Market Share by Type (2012-2017)
    5.3 Global Oral hypoglycemic agents and insulin analogues Price by Type (2012-2017)
    5.4 Global Oral hypoglycemic agents and insulin analogues Production Growth by Type (2012-2017)

6 Global Oral hypoglycemic agents and insulin analogues Market Analysis by Application
    6.1 Global Oral hypoglycemic agents and insulin analogues Consumption and Market Share by Application (2012-2017)
    6.2 Global Oral hypoglycemic agents and insulin analogues Consumption Growth Rate by Application (2012-2017)
    6.3 Market Drivers and Opportunities
        6.3.1 Potential Applications
        6.3.2 Emerging Markets/Countries

7 Global Oral hypoglycemic agents and insulin analogues Manufacturers Profiles/Analysis
    7.1 Sanofi-Aventis
        7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.1.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
            7.1.2.1 Product A
            7.1.2.2 Product B
        7.1.3 Sanofi-Aventis Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.1.4 Main Business/Business Overview
    7.2 Ganlee
        7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.2.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
            7.2.2.1 Product A
            7.2.2.2 Product B
        7.2.3 Ganlee Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.2.4 Main Business/Business Overview
    7.3 Biocon
        7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.3.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
            7.3.2.1 Product A
            7.3.2.2 Product B
        7.3.3 Biocon Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.3.4 Main Business/Business Overview
    7.4 Novo Nordisk
        7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.4.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
            7.4.2.1 Product A
            7.4.2.2 Product B
        7.4.3 Novo Nordisk Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.4.4 Main Business/Business Overview
    7.5 Eli Lilly
        7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.5.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
            7.5.2.1 Product A
            7.5.2.2 Product B
        7.5.3 Eli Lilly Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.5.4 Main Business/Business Overview
    7.6 Tonghua Dongbao
        7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.6.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
            7.6.2.1 Product A
            7.6.2.2 Product B
        7.6.3 Tonghua Dongbao Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.6.4 Main Business/Business Overview
    7.7 United Laboratory
        7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.7.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
            7.7.2.1 Product A
            7.7.2.2 Product B
        7.7.3 United Laboratory Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.7.4 Main Business/Business Overview
    7.8 Jiangsu Wanbang
        7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.8.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
            7.8.2.1 Product A
            7.8.2.2 Product B
        7.8.3 Jiangsu Wanbang Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.8.4 Main Business/Business Overview

8 Oral hypoglycemic agents and insulin analogues Manufacturing Cost Analysis
    8.1 Oral hypoglycemic agents and insulin analogues Key Raw Materials Analysis
       8.1.1 Key Raw Materials
       8.1.2 Price Trend of Key Raw Materials
       8.1.3 Key Suppliers of Raw Materials
       8.1.4 Market Concentration Rate of Raw Materials
    8.2 Proportion of Manufacturing Cost Structure
       8.2.1 Raw Materials
       8.2.2 Labor Cost
       8.2.3 Manufacturing Expenses
    8.3 Manufacturing Process Analysis of Oral hypoglycemic agents and insulin analogues

9 Industrial Chain, Sourcing Strategy and Downstream Buyers
    9.1 Oral hypoglycemic agents and insulin analogues Industrial Chain Analysis
    9.2 Upstream Raw Materials Sourcing
    9.3 Raw Materials Sources of Oral hypoglycemic agents and insulin analogues Major Manufacturers in 2015
    9.4 Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders
    10.1 Marketing Channel
        10.1.1 Direct Marketing
        10.1.2 Indirect Marketing
        10.1.3 Marketing Channel Development Trend
    10.2 Market Positioning
        10.2.1 Pricing Strategy
        10.2.2 Brand Strategy
        10.2.3 Target Client
    10.3 Distributors/Traders List

11 Market Effect Factors Analysis
    11.1 Technology Progress/Risk
        11.1.1 Substitutes Threat
        11.1.2 Technology Progress in Related Industry
    11.2 Consumer Needs/Customer Preference Change
    11.3 Economic/Political Environmental Change

12 Global Oral hypoglycemic agents and insulin analogues Market Forecast (2017-2022)
    12.1 Global Oral hypoglycemic agents and insulin analogues Capacity, Production, Revenue Forecast (2017-2022)
        12.1.1 Global Oral hypoglycemic agents and insulin analogues Capacity, Production and Growth Rate Forecast (2017-2022)
        12.1.2 Global Oral hypoglycemic agents and insulin analogues Revenue and Growth Rate Forecast (2017-2022)
        12.1.3 Global Oral hypoglycemic agents and insulin analogues Price and Trend Forecast (2017-2022)
    12.2 Global Oral hypoglycemic agents and insulin analogues Production, Consumption , Import and Export Forecast by Region (2017-2022)
        12.2.1 North America Oral hypoglycemic agents and insulin analogues Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.2 Europe Oral hypoglycemic agents and insulin analogues Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.3 China Oral hypoglycemic agents and insulin analogues Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.4 Japan Oral hypoglycemic agents and insulin analogues Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.5 Southeast Asia Oral hypoglycemic agents and insulin analogues Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.6 India Oral hypoglycemic agents and insulin analogues Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
    12.3 Global Oral hypoglycemic agents and insulin analogues Production, Revenue and Price Forecast by Type (2017-2022)
    12.4 Global Oral hypoglycemic agents and insulin analogues Consumption Forecast by Application (2017-2022)

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology/Research Approach
        14.1.1 Research Programs/Design
        14.1.2 Market Size Estimation
        14.1.3 Market Breakdown and Data Triangulation
    14.2 Data Source
        14.2.1 Secondary Sources
        14.2.2 Primary Sources
    14.3 Disclaimer